Sutro Biopharma Inc (NASDAQ:STRO) has a beta value of 1.70 and has seen 1.03 million shares traded in the last trading session. The company, currently valued at $49.87M, closed the last trade at $0.60 per share which meant it lost -$0.05 on the day or -8.50% during that session. The STRO stock price is -880.0% off its 52-week high price of $5.88 and -5.0% below the 52-week low of $0.63. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.3 million shares traded. The 3-month trading volume is 1.35 million shares.
The consensus among analysts is that Sutro Biopharma Inc (STRO) is Buy stock at the moment, with a recommendation rating of 2.36. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 5 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight.
Sutro Biopharma Inc (NASDAQ:STRO) trade information
Sporting -8.50% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the STRO stock price touched $0.60 or saw a rise of 24.81%. Year-to-date, Sutro Biopharma Inc shares have moved -67.65%, while the 5-day performance has seen it change -20.63%. Over the past 30 days, the shares of Sutro Biopharma Inc (NASDAQ:STRO) have changed -58.52%. Short interest in the company has seen 4.64 million shares shorted with days to cover at 2.92.
Wall Street analysts have a consensus price target for the stock at $12, which means that the shares’ value could jump 95.0% from current levels. The projected low price target is $2.0 while the price target rests at a high of $12.0. In that case, then, we find that the current price level is -1900.0% off the targeted high while a plunge would see the stock gain -233.33% from current levels.
Sutro Biopharma Inc (STRO) estimates and forecasts
The company’s shares have lost -82.99% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -4.05% over the past 5 years. Earnings growth for 2025 is a modest 30.93% while over the next 5 years, the company’s earnings are expected to increase by 32.32%.
STRO Dividends
Sutro Biopharma Inc is expected to release its next earnings report on 2025-Mar-12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Sutro Biopharma Inc (NASDAQ:STRO)’s Major holders
Insiders own 4.10% of the company shares, while shares held by institutions stand at 73.94% with a share float percentage of 77.10%. Investors are also buoyed by the number of investors in a company, with Sutro Biopharma Inc having a total of 163.0 institutions that hold shares in the company. The top two institutional holders are SUVRETTA CAPITAL MANAGEMENT, LLC with over 7.71 million shares worth more than $22.59 million. As of 2024-06-30, SUVRETTA CAPITAL MANAGEMENT, LLC held 9.4906% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 6.91 million shares as of 2024-06-30. The firm’s total holdings are worth over $20.25 million and represent 8.5082% of shares outstanding.
